Important Notice for Pacira BioSciences, Inc. Shareholders
New York, NY, March 10, 2025 – The Gross Law Firm announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of shareholders of Pacira BioSciences, Inc. (PCRX) who purchased shares between February 1, 2023, and October 31, 2024.
Details of the Lawsuit
The complaint alleges that Pacira BioSciences and certain of its officers and directors violated the Securities Exchange Act of 1934 by making false and misleading statements and failing to disclose material information to the investing public. Specifically, the lawsuit alleges that the defendants made false and misleading statements regarding the safety and efficacy of Pacira’s EXPAREL product, as well as the company’s financial performance and prospects.
Effect on Shareholders
If you purchased Pacira BioSciences, Inc. shares during the class period and suffered a loss, you may be entitled to compensation. The lead plaintiff must apply to the Court by April 9, 2025, to be appointed as the representative of the class. The lead plaintiff will determine the final settlement of the case and the distribution of the damages to the class members.
Effect on the World
The lawsuit against Pacira BioSciences, Inc. is significant because it raises concerns about the integrity of the pharmaceutical industry and the importance of accurate and transparent communication with investors. If the allegations are proven true, it could lead to increased scrutiny of other companies in the industry and potential regulatory action. It could also impact the confidence of investors in the biotech sector as a whole.
Conclusion
Shareholders of Pacira BioSciences, Inc. who purchased shares between February 1, 2023, and October 31, 2024, are encouraged to contact The Gross Law Firm to discuss their legal rights and potential eligibility to be a lead plaintiff in the class action lawsuit. The lawsuit alleges that the company and its executives made false and misleading statements regarding the safety and efficacy of Pacira’s EXPAREL product and the company’s financial performance and prospects. If you are a shareholder and wish to discuss this matter further, please contact The Gross Law Firm as soon as possible.
- Shareholders who purchased Pacira BioSciences, Inc. shares between February 1, 2023, and October 31, 2024, are encouraged to contact The Gross Law Firm
- The lawsuit alleges that the company and its executives made false and misleading statements regarding the safety and efficacy of Pacira’s EXPAREL product and the company’s financial performance and prospects
- If you are a shareholder and wish to discuss this matter further, please contact The Gross Law Firm as soon as possible
